Translating cancer 'omics' to improved outcomes.

The genomics era has yielded great advances in the understanding of cancer biology. At the same time, the immense complexity of the cancer genome has been revealed, as well as a striking heterogeneity at the whole-genome (or omics) level that exists between even histologically similar tumors. The vast accrual and public availability of multi-omics databases with associated clinical annotation including tumor histology, patient response, and outcome are a rich resource that has the potential to lead to rapid translation of high-throughput omics to improved overall survival. We focus on the unique advantages of a multidimensional approach to genomic analysis in this new high-throughput omics age and discuss the implications of the changing cancer demographic to translational omics research.

[1]  T. Stricker,et al.  Molecular profiling of cancer--the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. , 2011, Seminars in oncology.

[2]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[3]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[4]  M. McDevitt,et al.  SNP Array Karyotyping Allows for the Detection of Uniparental Disomy and Cryptic Chromosomal Abnormalities in MDS/MPD-U and MPD , 2007, PloS one.

[5]  Jeremiah D. Degenhardt,et al.  A Simple Genetic Architecture Underlies Morphological Variation in Dogs , 2010, PLoS biology.

[6]  A. Barabasi,et al.  Interactome Networks and Human Disease , 2011, Cell.

[7]  Kunihiko Kobayashi,et al.  3) Non-small Cell Lung Cancer , 2012 .

[8]  G. Giaccone,et al.  American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  William Pao,et al.  Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer , 2010, Nature Reviews Cancer.

[10]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[11]  M. Somerfield,et al.  American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Seung-Yong Jeong,et al.  Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer , 2011, Cancer Chemotherapy and Pharmacology.

[13]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[14]  H. Varmus,et al.  Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors. , 2006, Genes & development.

[15]  Richard Doll,et al.  Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies , 2000, BMJ : British Medical Journal.

[16]  D. Hungerford.  Chromosome studies in human leukemia. 1. Acute leukemia in children. , 1961, Journal of the National Cancer Institute.

[17]  R. Jaenisch,et al.  Chromosomal Instability and Tumors Promoted by DNA Hypomethylation , 2003, Science.

[18]  C. Hudis.  Trastuzumab--mechanism of action and use in clinical practice. , 2007, The New England journal of medicine.

[19]  Bradley P. Coe,et al.  Integrating the multiple dimensions of genomic and epigenomic landscapes of cancer , 2010, Cancer and Metastasis Reviews.

[20]  L. Chin,et al.  Chimeric mouse tumor models reveal differences in pathway activation between ERBB family– and KRAS-dependent lung adenocarcinomas , 2010, Nature Biotechnology.

[21]  W. Pao,et al.  How genetically engineered mouse tumor models provide insights into human cancers. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Jannik N. Andersen,et al.  Cancer genomics: from discovery science to personalized medicine , 2011, Nature Medicine.

[23]  J. Mao,et al.  Cancer evolution and individual susceptibility. , 2011, Integrative biology : quantitative biosciences from nano to macro.

[24]  K. Syrigos,et al.  Targeted therapy for gastrointestinal stromal tumors: current status and future perspectives , 2010, Cancer and Metastasis Reviews.

[25]  Joshua D. Swartz,et al.  Mapping DNA structural variation in dogs. , 2009, Genome research.

[26]  Boris Pasche,et al.  Whole-genome sequencing: a step closer to personalized medicine. , 2011, JAMA.

[27]  Charles Swanton,et al.  Breast cancer genome heterogeneity: a challenge to personalised medicine? , 2011, Breast Cancer Research.

[28]  H. Ohtsuki,et al.  Accumulation of driver and passenger mutations during tumor progression , 2009, Proceedings of the National Academy of Sciences.

[29]  T. Mikkelsen,et al.  The NIH Roadmap Epigenomics Mapping Consortium , 2010, Nature Biotechnology.

[30]  G. Poste.  Bring on the biomarkers , 2011, Nature.

[31]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[32]  M. Toyota,et al.  A Novel Correlation between LINE-1 Hypomethylation and the Malignancy of Gastrointestinal Stromal Tumors , 2010, Clinical Cancer Research.

[33]  Julie O. Culver,et al.  Genetics, genomics, and cancer risk assessment , 2011, CA: a cancer journal for clinicians.

[34]  C. Gatsonis,et al.  Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .

[35]  Shiladitya Sengupta,et al.  Inactivation of human mutL homolog 1 and mutS homolog 2 genes in head and neck squamous cell carcinoma tumors and leukoplakia samples by promoter hypermethylation and its relation with microsatellite instability phenotype , 2007, Cancer.

[36]  E. Ostrander,et al.  Man's best friend becomes biology's best in show: genome analyses in the domestic dog. , 2010, Annual review of genetics.

[37]  A. Russo,et al.  Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? , 2010, Cancer treatment reviews.

[38]  A. Børresen-Dale,et al.  COMPLEX LANDSCAPES OF SOMATIC REARRANGEMENT IN HUMAN BREAST CANCER GENOMES , 2009, Nature.

[39]  G. Church,et al.  The Personal Genome Project , 2005, Molecular systems biology.

[40]  B. Druker,et al.  Translation of the Philadelphia chromosome into therapy for CML. , 2008, Blood.

[41]  N. Rosen,et al.  Mutant BRAF melanomas--dependence and resistance. , 2011, Cancer cell.

[42]  M. Loda,et al.  Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. , 1997, Cancer research.

[43]  Michael E Phelps,et al.  Systems Biology and New Technologies Enable Predictive and Preventative Medicine , 2004, Science.

[44]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[45]  Li Ding,et al.  Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. , 2011, JAMA.

[46]  J. Minna,et al.  ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. , 2010, Cancer cell.

[47]  P. Jänne,et al.  Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[48]  E. Birney,et al.  A small cell lung cancer genome reports complex tobacco exposure signatures , 2009, Nature.

[49]  Michael Peyton,et al.  Alterations in Genes of the EGFR Signaling Pathway and Their Relationship to EGFR Tyrosine Kinase Inhibitor Sensitivity in Lung Cancer Cell Lines , 2009, PloS one.

[50]  A. Cassidy,et al.  Hypomethylation of retrotransposable elements correlates with genomic instability in non‐small cell lung cancer , 2009, International journal of cancer.

[51]  B. Gillespie,et al.  Patterns of absolute risk of lung cancer mortality in former smokers. , 1993, Journal of the National Cancer Institute.

[52]  Motohiro Kato,et al.  Highly sensitive method for genomewide detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix single-nucleotide-polymorphism genotyping microarrays. , 2007, American journal of human genetics.

[53]  A. Sparks,et al.  The mutation spectrum revealed by paired genome sequences from a lung cancer patient , 2010, Nature.

[54]  Inyoul Lee,et al.  Systems Biology and the Discovery of Diagnostic Biomarkers , 2010, Disease markers.

[55]  Shuji Ogino,et al.  Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: Cohort study and literature review , 2011, International journal of cancer.

[56]  T. C. McLoud,et al.  Lung carcinoma. , 1999, Clinics in chest medicine.

[57]  M. Spitz,et al.  Lung carcinoma in former smokers , 1996, Cancer.

[58]  J. Uhm.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .

[59]  Y. Lussier,et al.  The Emergence of Genome-Based Drug Repositioning , 2011, Science Translational Medicine.

[60]  Charles M. Perou,et al.  Deconstructing the molecular portraits of breast cancer , 2010, Molecular oncology.

[61]  Elias Campo Guerri,et al.  International network of cancer genome projects , 2010 .

[62]  Peter H. Baenziger,et al.  In silico functional profiling of human disease‐associated and polymorphic amino acid substitutions , 2010, Human mutation.

[63]  B. Firestone.  The challenge of selecting the 'right' in vivo oncology pharmacology model. , 2010, Current opinion in pharmacology.

[64]  Richard Simon,et al.  Identifying cancer driver genes in tumor genome sequencing studies , 2011, Bioinform..

[65]  Ken Chen,et al.  Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. , 2011, JAMA.

[66]  Arlene A. Forastiere,et al.  Head and Neck , 1998, Indian Journal of Radiology and Imaging.

[67]  C. Papadimitriou,et al.  Mechanisms of resistance to epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small-cell lung cancer: clinical and molecular considerations. , 2011, Current medicinal chemistry.

[68]  P. Nederlof,et al.  EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[69]  S. Hoffmann.  Computational analysis of high throughput sequencing data. , 2011, Methods in molecular biology.

[70]  S. De,et al.  DNA secondary structures and epigenetic determinants of cancer genome evolution , 2010, Nature Structural &Molecular Biology.

[71]  T. Fojo,et al.  Biologically Targeted Cancer Therapy and Marginal Benefits: Are We Making Too Much of Too Little or Are We Achieving Too Little by Giving Too Much? , 2010, Clinical Cancer Research.

[72]  Calum MacAulay,et al.  Oncogene Mutations, Copy Number Gains and Mutant Allele Specific Imbalance (MASI) Frequently Occur Together in Tumor Cells , 2009, PloS one.

[73]  J. Ahn,et al.  The 18p11.22 locus is associated with never smoker non-small cell lung cancer susceptibility in Korean populations , 2011, Human Genetics.

[74]  R. Rizwana,et al.  CpG methylation reduces genomic instability. , 1999, Journal of Cell Science.

[75]  Predrag Radivojac,et al.  Gain and Loss of Phosphorylation Sites in Human Cancer , 2022 .

[76]  C. Greenman,et al.  Germline Fitness-Based Scoring of Cancer Mutations , 2011, Genetics.

[77]  O. Sieber,et al.  APC and the three-hit hypothesis , 2009, Oncogene.

[78]  R. Hampson.  Selection for genome instability by DNA damage in human cells: unstable microsatellites and their consequences for tumourigenesis. , 1997, Radiation oncology investigations.

[79]  J. Reid,et al.  Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[80]  Raj Chari,et al.  An integrative multi-dimensional genetic and epigenetic strategy to identify aberrant genes and pathways in cancer , 2010, BMC Systems Biology.

[81]  M. Stratton,et al.  Statistical Analysis of Pathogenicity of Somatic Mutations in Cancer , 2006, Genetics.

[82]  E. Petricoin,et al.  Cancer biomarkers: closer to delivering on their promise. , 2011, Cancer Cell.

[83]  N. M. A. El-Maqsoud,et al.  Head and neck squamous cell carcinoma: mismatch repair immunohistochemistry and promoter hypermethylation of hMLH1 gene. , 2011, American journal of otolaryngology.

[84]  L. Santarpia,et al.  Breast cancer assessment tools and optimizing adjuvant therapy , 2010, Nature Reviews Clinical Oncology.

[85]  H. Aburatani,et al.  Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.

[86]  W. Lam,et al.  Mitochondrial DNA mutations in respiratory complex‐I in never‐smoker lung cancer patients contribute to lung cancer progression and associated with EGFR gene mutation , 2012, Journal of cellular physiology.

[87]  T. Jacks,et al.  Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase , 2009, Nature Protocols.

[88]  Brynn H Voy,et al.  Genetic analysis in the Collaborative Cross breeding population. , 2011, Genome research.

[89]  Keith Robison,et al.  Application of second-generation sequencing to cancer genomics , 2010, Briefings Bioinform..

[90]  L. Garraway,et al.  Oncogenic Activating Mutations Are Associated with Local Copy Gain , 2009, Molecular Cancer Research.

[91]  Giovanni Parmigiani,et al.  Patient-oriented gene set analysis for cancer mutation data , 2010, Genome Biology.

[92]  G. Canellos,et al.  Chronic granulocytic leukemia. , 1976, The Medical clinics of North America.

[93]  Yuan Qi,et al.  Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA , IDH 1 , EGFR , and NF 1 Citation Verhaak , 2010 .

[94]  P. Nowell,et al.  Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. , 1961, Journal of the National Cancer Institute.

[95]  Misha Angrist,et al.  Personal genomes in progress: from the Human Genome Project to the Personal Genome Project , 2010, Dialogues in clinical neuroscience.

[96]  L. Tanoue,et al.  Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer , 2012 .

[97]  Q. Hasan,et al.  Microsatellite instability analysis and its correlation with hMLH1 repair gene hypermethylation status in esophageal pathologies including cancers. , 2010, Cancer biomarkers : section A of Disease markers.

[98]  C. E. Alvarez,et al.  Dog models of naturally occurring cancer. , 2011, Trends in molecular medicine.

[99]  Virginia Espina,et al.  Molecular Profiling , 2012, Methods in Molecular Biology.

[100]  M. McDevitt,et al.  250K single nucleotide polymorphism array karyotyping identifies acquired uniparental disomy and homozygous mutations, including novel missense substitutions of c-Cbl, in myeloid malignancies. , 2008, Cancer research.

[101]  Andrew Menzies,et al.  Architectures of somatic genomic rearrangement in human cancer amplicons at sequence-level resolution. , 2007, Genome research.

[102]  F. Bertucci,et al.  Integrated Genomic Analysis of Breast Cancers , 2012, Balkan journal of medical genetics : BJMG.

[103]  Kenneth Offit,et al.  Personalized medicine: new genomics, old lessons , 2011, Human Genetics.

[104]  C. Sawyers.  The cancer biomarker problem , 2008, Nature.

[105]  J. Baselga,et al.  The Evolving War on Cancer , 2011, Cell.

[106]  Renato Martins,et al.  Non-small cell lung cancer. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[107]  Ruth Etzioni,et al.  Early detection: The case for early detection , 2003, Nature Reviews Cancer.

[108]  Steven J. M. Jones,et al.  Evolution of an adenocarcinoma in response to selection by targeted kinase inhibitors , 2010, Genome Biology.

[109]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[110]  Susumu Goto,et al.  KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..